Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Ocular Therapeutix (OCUL) Net Margin (2016 - 2025)

Ocular Therapeutix has reported Net Margin over the past 13 years, most recently at 492.45% for Q4 2025.

  • Quarterly results put Net Margin at 492.45% for Q4 2025, down 20553.0% from a year ago — trailing twelve months through Dec 2025 was 507.2% (down 24815.0% YoY), and the annual figure for FY2025 was 507.2%, down 24815.0%.
  • Net Margin for Q4 2025 was 492.45% at Ocular Therapeutix, down from 467.35% in the prior quarter.
  • Over the last five years, Net Margin for OCUL hit a ceiling of 142.09% in Q3 2023 and a floor of 589.6% in Q1 2025.
  • Median Net Margin over the past 5 years was 189.7% (2021), compared with a mean of 259.05%.
  • Biggest five-year swings in Net Margin: soared 106001bps in 2021 and later tumbled -37472bps in 2025.
  • Ocular Therapeutix's Net Margin stood at 160.25% in 2021, then grew by 8bps to 147.67% in 2022, then fell by -4bps to 153.65% in 2023, then crashed by -87bps to 286.92% in 2024, then tumbled by -72bps to 492.45% in 2025.
  • The last three reported values for Net Margin were 492.45% (Q4 2025), 467.35% (Q3 2025), and 499.31% (Q2 2025) per Business Quant data.